The US-based biotechnology company Inari has completed a $144 million fundraise, bringing its cumulative equity raised to more than $720 million. The round received support from new investors, who represented most of the capital raised in the round, as well as existing investors including Hanwha Impact, NGS Super, the State of Michigan Retirement System and Flagship Pioneering. Inari intends to utilise the capital raised to support its long-term growth.